A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: Exploring the causes of heterogeneity
267
TL;DR: The data highlight that comorbidity and behavioral aspects of depression need to be measured and controlled in future prospective and experimental research testing the inflammatory hypothesis of depression.
read more
Abstract: Epidemiological evidence for the inflammatory hypothesis of depression is largely cross-sectional; people with depression have elevated levels of circulating pro-inflammatory markers compared to people without depression. The limitation of cross sectional research is the potential for extraneous factors to influence observed effects. The purpose of this meta-analysis of cross-sectional studies of interleukin(IL)-6 and IL-10 in people with and without depression is to provide a targeted analysis of potential moderator factors relating to the diagnosis of depression and to physical and psychiatric comorbidity. Electronic searches of Embase and Medline databases were conducted using subject headings "interleukin-6" or "interleukin-10" and those relating to depression. Studies were included if they measured circulating marker levels in serum or plasma in a group of people with and without depressive symptoms (99 studies for IL-6, 19 studies for IL-10). IL-6 was elevated in depressed compared to non-depressed groups (d = 0.46, 99% CI 0.34 to 0.58, I(2) = 85.9%). This effect was larger in subgroups where depressive disorders were diagnosed compared to those with only depressive symptoms via standardized inventory, and subgroups where participants were recruited from inpatient or outpatient settings compared to the general community. The effect was also larger in those who were not selected for a particular comorbidity compared to those selected for cardiovascular disease. IL-10 effect size was not significant (d = -0.31, 99% CI -0.95 to 0.32, I(2) = 94.1%) which was not accounted for in subgroup analyses or meta-regression, indicating there is not a global elevation in cytokines. These data highlight that comorbidity and behavioral aspects of depression need to be measured and controlled in future prospective and experimental research testing the inflammatory hypothesis of depression.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Investigating neurobiological mechanisms linking depression and inflammation
Kyoko Hasebe
- 01 May 2017
TL;DR: There is evidence that diet can change the gut microbial population and that this may be linked to changes in mood, and this is linked to novel treatments for this widespread and debilitating disorder.
4
Interleukin-10 promoter gene polymorphisms are associated with the first major depressive episode in chronic hepatitis C patients.
Luciana Rodrigues da Cunha,Diego Alves Vieira,Yala Gramigna Giampietro,Adriana Dias Gomes,César Lúcio Lopes de Faria,Fabrício Freire de Melo,Rosângela Teixeira,Andréa Teixeira de Carvalho,Luciana Maria Oliveira,Olindo Assis Martins Filho,Gifone A. Rocha,Dulciene M.M. Queiroz,Fernando Silva Neves,Luciana Diniz Silva +13 more
TL;DR: This is the first study to demonstrate that the IL10 low producer ATA haplotype is associated with the first MDE in patients with CHC.
4
Translational research into frailty from bench to bedside: Salivary biomarkers for inflammaging
Alfonssina Niebla-Cardenas,Halin Bareke,Pablo Juanes-Velasco,Alicia Landeira-Viñuela,Ángela P Hernández,Enrique Montalvillo,Rafael Góngora,Eva M. Arroyo-Anlló,Ana Silvia Puente-González,Roberto Méndez-Sánchez,Manuel Fuentes +10 more
TL;DR: In this paper , the authors describe the current knowledge on the association between frailty and the inflammatory process and discuss methods to identify putative biomarkers in salivary fluids to predict this syndrome.
4
Psychobiotics: A Novel Approach to the Treatment ofMental Diseases
E A Ushkalova,AnnaV Ushkalova,KarinaE Zatolochina +2 more
- 31 Jul 2019
TL;DR: The need to seek for new approaches to the prevention/treatment of mental disorders, medical comorbidity and adverse drug reactions of current pharmacotherapy is dictated.
3
Trajectories of depressive symptoms during pregnancy and risk of premature birth: A multicenter and prospective cohort study
Ji-Chun Yang,Yimin Qu,Yongle Zhan,Hai-Wen Ma,Xiaoxiu Li,Dongmei Man,Hongguo Wu,Ping Huang,Liangkun Ma,Yu Jiang +9 more
TL;DR: Wang et al. as mentioned in this paper explored the associations between the trajectories of depressive symptoms during pregnancy and risk of preterm birth (PTB) using group-based trajectory modeling (GBTM), propensity score-based inverse probability of treatment weighting (IPTW), and logistic regression.
3
References
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
A rating scale for depression
TL;DR: The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information.
32.8K
•Book
Introduction to Meta-Analysis
Michael Borenstein,Larry V. Hedges,Julian P T Higgins,Hannah R. Rothstein +3 more
- 27 Apr 2009
Estimating the mean and variance from the median, range, and the size of a sample.
TL;DR: Two simple formulas are found that estimate the mean using the values of the median, low and high end of the range, and n (the sample size) and these hope to help meta-analysts use clinical trials in their analysis even when not all of the information is available and/or reported.